CD274 and non-small cell lung carcinoma: For instance, nivolumab monotherapy at 3 mg/kg every 2 weeks in the CheckMate 026 (NCT02041533) study did not lead to improvements in PFS or OS as a first-line systemic treatment for patients with advanced NSCLC and PD-L1 expression of 5% or greater [92].